Stockreport

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

Mersana Therapeutics, Inc.  (MRSN) 
Last mersana therapeutics, inc. earnings: 2/28 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: mersana.com/about-mersana
PDF - Emiltatug ledadotin observed to be generally well tolerated with differentiated safety and tolerability profile- Promising clinical activity observed in patients with [Read more]